May 10, 2017

Volume 23

Issue 5

# ETF & MUTUAL FUND UPDATE

## In This Issue:

Page 1: Why Markets are Excited about a Trump Tax Cut

Page 2: ETF Spotlight: Horizons Medical Marijuana ETF

Page 5: Paterson Recommended List

| Market Radar | | |
|---|---|---|
| **Markets** | **TSX Composite** | **S&P 500** |
| P/E | 19.24 | 21.27 |
| Yield (%) | 3.03 | 2.39 |
| YTD Performance (%) | 1.74 | 7.09 |
| **Top Performers** | **ETF** | **Mutual Fund** |
| 1-Month | First Asset European Bank | RBC European Mid-Cap Equity |
| YTD | Purpose Enhanced US Equity | Excel New India Leaders |
| 3-Year | iShares TSX Cons. Staples | TD Science and Technology |

Market data as of May 8, 2017; top performers as of month-end.

Note: We are no longer including leveraged ETFs in top performers list

# Why Markets are Excited about a Trump Tax Cut and how to Play it in a Fund

By Ryan Modesto, CFA

### Putting Cash to Work

News is starting to hit that President Donald Trump is planning to decrease corporate tax rates from 35% to 15%. We won’t bother getting into the likelihood of this occurring, or whether the actual tax rate will be anywhere near 15% or even if corporations actually pay a 35% tax or potential budget issues. We wanted to keep this one quick and simple, and dive into why the markets are excited by the idea of a slash to the corporate tax rate. Put simply, it is all about the compounding of returns.

If you look at the change in the tax rate simply as a one-off ‘bonus’, the lower rate is nice but not the whole story. Let’s say company X makes $100,000 a year before tax. After the company pays taxes they would make $65,000. In other words, of the $100,000 the company ‘earned’, they only get to keep $65,000 of the total for reinvesting or taking out of the business. With the change to a 15% rate, this amount increases to $85,000 or a 30% increase. So, while it is a nice bump in returns right off the bat, it gets better.

The real story is what that increase amounts to over the long term. Markets are always looking forward and taking future cash flows and discounting them back to the present. In the case of a tax rate decline, all companies in theory get a ‘raise’ that lasts indefinitely. Going back to our original example, the additional $20,000 over ten years amounts to $140,000 in value when discounted at 7%. If we simply assume that the tax rate remains in perpetuity, the total value comes in at just shy of $286,000. This could be four years worth of after tax earnings being added to a company, all because of a cut in tax rates.

### Putting Cash to Work

Adding a bit of a cherry on the top to a change like this is determining what a company does with the extra cash it has received. If the company takes the funds and increases dividends, buys back shares or invests in new projects that generate more returns in perpetuity, it can be seen that the impacts can become quite impressive over the years. Anyone who is familiar with the power of compounding will know the power that returns generating returns can have over a number of


Continued on Page 2


Please perform your own due diligence before making investment decisions. The contents of this newsletter do not constitute a recommendation to buy or sell securities.
© 2017 5i Research Inc.

years. Unfortunately, this is the part that is hard to quantify. While some of the impact of a tax rate change is certainly priced in, what markets will have a harder time doing is determining what is done with the cash (if a cut in tax rates occurs), what kinds of returns that cash can generate and for how long.

With the help of some data that can be found here (http://pages.stern.nyu.edu/~adamodar/New_Home_Page/datafile/taxrate.html), we are going to look at three industries that may have the most to gain from these tax changes and the options available to invest.

While there are various industries paying close to the 30% tax rate, the ones that are easiest to silo into a specific fund are Transportation, Regional Banks and Homebuilding. We do note that most of these options will be USD traded. Below are a few options from each industry that may see a sustained boost if or when any tax changes come into effect in the US.

Image 1: ETFs to Play a Tax Cut

| Name | Ticker | MER | Performance (YTD) |
|---|---|---|---|
| Transportation – Rail and air and tucking | | | |
| iShares Transportation Average ETF | IYT | 0.44% | 1.68% |
| SPDR® S&P Transportation ETF | XTN | 0.35% | 0.91% |
| Regional Banks | | | |
| SPDR® S&P Regional Banking ETF | KRE | 0.35% | -1.00% |
| iShares U.S. Regional Banks ETF | IAT | 0.44% | -0.77% |
| Homebuilding | | | |
| iShares U.S. Home Construction ETF | ITB | 0.44% | 19.03% |
| SPDR® S&P Homebuilders ETF | XHB | 0.35% | 12.97% |

Notes: IAT has significant concentration in top two holdings; adds risk.
ITB has much more concentration risk in select names.

## ETF Spotlight: Horizons Medical Marijuana Life Sciences ETF

By Michael Southern, CFA

Just what the doctor ordered! Finally, there's a marijuana exchange-traded fund (ETF) focusing primarily on Canadian marijuana companies.

On April 05, 2017, Horizons ETFs launched the Horizons Medical Marijuana Life Sciences ETF (HMMJ), which seeks to replicate, to the extent possible, the performance of the North American Medical Marijuana Index, net of expenses. The index is designed to provide exposure to the performance of a basket of North American publicly-listed life sciences companies with significant business activities in the marijuana industry.

### High Industry Expectations

With all the initial excitement that has surrounded the industry, it was simply a matter of time before we saw an ETF platform jump at the opportunity. As per data from Horizons, the North American medical marijuana market posted USD $6.7 billion in revenues in 2016, up 30.0% from the previous year. The Government of Canada reports that Canadians continue to use cannabis at some of the highest rates in the world. In 2015, 21.0% of youth and 30.0% of young adults reported using cannabis within the last year.

A popular 2016 study from Deloitte estimated that a legal market for recreational marijuana – including growing and distribution, pot paraphernalia, increased tourism and business taxes – would amount to $12.7 billion to $22.6 billion annually. The study estimates that marijuana sales, even initially, would be at least as large as hard liquor sales in Canada, at around $5 billion annually, but could be as large as $8.7 billion, making them as large as wine sales.

The future aside, using data from Health Canada, we can easily see the tremendous growth the industry has already achieved. As of the last quarter, there was a total of 129,876 registered users which represents an increase of 227.4% over the previous year, or quarterly


Continued on Page 3

Please perform your own due diligence before making investment decisions. The contents of this newsletter do not constitute a recommendation to buy or sell securities.
© 2017 5i Research Inc.

growth of 34.5%. Licensed producers sold 5,134 kilograms of dried cannabis and 4,109 kilograms of cannabis oil. In the previous year's quarter, these figures were 2,481 kilograms and 3 kilograms, respectively.




## The Index and Underlying Portfolio

HMMJ is currently comprised of 15 stocks. Constituents are listed on North American public equity markets with business activities that include biopharmaceuticals, medical manufacturing, distribution, bio products and other ancillary businesses to the marijuana industry.

This is important from a diversification perspective as the current 'pure play' marijuana industry suffers from a lack of a large number of liquid and actively trading marijuana companies

Image 2: HMMJ Portfolio

| Stock Name | Weight |
|---|---|
| Aurora Cannabis | 10.3% |
| Insys Therapeutics | 9.8% |
| Zynerba Pharmaceuticals | 9.4% |
| Aphria | 9.3% |
| Canopy Growth Corp. | 9.1% |
| Scotts Miracle-Gro | 8.9% |
| GW Pharmaceuticals | 8.7% |
| Cronos Group | 8.0% |
| Organigram | 5.8% |
| Cannimed Therapeutics | 5.3% |
| Supreme Pharmaceuticals | 4.5% |
| Emblem Corp | 4.4% |
| ICC International Cannabis | 2.9% |
| Emerald Health Therapeutics | 2.7% |
| The Hydropothecary Corp | 0.8% |
| Cash | 0.2% |




with large capitalizations. By including secondary or tertiary industries that support marijuana, HMMJ maintains the diversification 'spirit of the law' ETFs were originally built upon. The largest stock in the fund is US-listed lawn care provider Scotts Miracle-Gro, which invests in hydroponics, soil, growing systems and lights for the marijuana sector. British pharmaceutical giant, GW Pharmaceuticals, which is US-listed, is also included due to its focus on developing cannabinoid-based medicine.

HMMJ will only invest in public companies that are involved in legal and regulated segments of the marijuana industry. HMMJ will not invest in any companies involved in the production or distribution of recreational marijuana, as it is still illegal under the federal laws of both the United States and Canada

Index components are weighted according to market capitalization subject to a cap of 10.0% for any single security. Any excess weight that results from this procedure will be redistributed proportionally among all index components with a weight of less than 10.0%. To be included in the index, stocks must meet the following criteria:

1. Minimum Market Capitalization of at least CAD $75 million.
2. Minimum Average Monthly Daily Value Traded of at least CAD $250,000.
3. Minimum Average Monthly Daily Volume Shares Traded of 75,000.

As with any fund with less than a year's worth of operating history, performance data is not available. However, we can say that the ETF initially began trading at a price of $10.25 per share, peaked at $12.40, and currently trades at $10.05.


Continued on Page 4


Please perform your own due diligence before making investment decisions. The contents of this newsletter do not constitute a recommendation to buy or sell securities.
© 2017 5i Research Inc.

## Risky Business

From a stock perspective, the industry has had an incredible run. Over the last 1-year, top ETF names like Aurora, Aphria and Canopy are all up over 250.0%. However, these gains have mostly come on the back of speculation and hype surrounding the industry. Very little of current prices reflect fundamentals and any sort of valuation analysis is useless. As an example, Aurora trades at a price-to-sales ratio of 55.0x, Aphria trades at a price-to-cash flow of 97.0x and Canopy trades at a price-to-earnings of 46.0x. To give you some context here, a top-tier technology company like Alphabet (formerly Google) trades at a P/S of 7.0x, P/CF of 17.0x, and P/E of 19.0x. Eventually, industry names need to start trading more on fundamentals and this poses a higher degree of risk for investors via a possible contraction in the valuation multiple.

Aside from the usual stock market and specific issuer risks of investing, HMMJ opens investors to an additional layer of concerns, namely industry risk and risks of transacting on smaller exchanges.

HMMJ can of course be expected to be more volatile than an investment fund with a more broadly diversified portfolio. The regulatory environment governing the medical and cannabis industries will continue to be subject to evolving regulation by governmental authorities. To date, Canada has legalized medical use of cannabis, but has not legalized the recreational use of cannabis. On April 13, 2017, the Minister of Justice Jody Wilson-Raybould and the Federal Liberal government introduced Bill C-45, the Cannabis Act, legislation that would begin the process of legalizing and regulating recreational marijuana by July 2018. If this bill is approved, Canada would become the second country in the world to legalize recreational cannabis, behind only Uruguay. However, there can be no assurance that federal or provincial laws legalizing and regulating the sale and use of cannabis will not be repealed or overturned, or that governmental authorities will not limit the application of such laws within their respective provinces.

## Closing Thoughts

Marijuana legalization was a high-profile campaign promise for the Trudeau government and efforts are underway to make this a reality. Many countries globally are looking to Canada as a leader in this area. For equity investors, this has been an excellent, and could continue to be, growth opportunity. For the higher risk equity investor with a time frame of at least three to five years (recreational legalization is only planned for 2018, after all) this is an attractive opportunity.

HMMJ makes investing in the industry easier for the average investor who is eager to buy the growth opportunity but has no specific outperform thesis on an individual industry name. Just keep in mind the heightened risk here. Gains have been excellent over the last few years but stocks already reflect the known potential of the industry. Where we go from here is anyone’s guess and investors should prepare themselves for a higher volatility ride.

Image 3: ETF Details

| ETF Details | Weight |
|---|---|
| Ticker | HMMJ |
| Price (2017/01/24) | 10.15 |
| MER % | 0.75% |
| Annualized inception return | N/A |
| Inception date: | 05/04/2017 |
| Top 5 % | 47.8% |
| Top 10 % | 84.4% |
| Total holdings | 14.0 |
| Yield % | N/A |
| Cash | 0.2% |


Continued on Page 5

Please perform your own due diligence before making investment decisions. The contents of this newsletter do not constitute a recommendation to buy or sell securities.
© 2017 5i Research Inc.

## Paterson Recommended List Review

By Dave Paterson

The year started out well for investors with gains, pretty much across the board. The FTSE/TMX Canadian Universe Bond Index gained 1.25% as yields finished the quarter roughly where they started. Corporate and long-term bonds outperformed, largely because of their higher yield to maturities.

Turning to equities, the S&P/TSX Composite Index was positive, generating 2.4% for investors. Global equities were also strong, with the S&P 500 gaining 5.0% and the MSCI EAFE Index rose by 6.6% CAD. The best performing region was Asia, ex-Japan, which gained 10.9% due to improving economic conditions.
I remain cautiously optimistic as there appears to be a period of synchronized global growth underway. In Canada, inflation remains relatively tame, with the latest CPI numbers coming in at 2% annualized, but if you back out food and energy, the numbers were even more muted at 1.7%. With very little inflation, it looks like the Bank of Canada will be on the sidelines for the near term, although the uptick in economic activity is on their radar. Some are now predicting a rate bump later this year, which is well ahead of previous expectations.

In the U.S., the economy has been showing some signs of strength, with improving consumer and business confidence, an uptick in manufacturing and non-manufacturing activity, initial jobless claims recently hitting a 45-year low, and many companies raising wages. Earnings growth has also been on the upswing, although growth levels remain well below historic averages. Some fear that if the U.S. Federal Reserve is too aggressive in their rate hikes, there will be a further damper on these already below trend growth rates.

Globally, European business surveys are at their highest levels in 6 years and productivity and industrial activity continues to grow, while China and other Asian economies are stabilizing.

There are still risks that need to be monitored. Perhaps the biggest, are valuation levels, particularly of U.S. stocks. They are trading well above normal, and we will need to see a strong upswing in corporate earnings to justify the current levels. Looking at Europe and Asia, I am becoming more optimistic, but am looking for further confirmation to support this outlook. In this environment, I remain confident in the picks on my Recommended List for the long-term. I did not make any additions or deletions this time around, but continue to watch a few funds particularly closely.

### Funds Added to the List

-None

### Funds Removed from the List

-None

### Funds of Note

**PowerShares 1-5 Year Laddered Corporate Bond Fund (AIM 53203 – Front End Units)** – This fund invests in short-term corporate bonds that have maturities of up to five years. The portfolio is structured with equal exposure to five different maturity buckets, that unsurprisingly range from one to five years. It used to be each of these buckets held only five bonds, but a couple years ago, this was changed, so that at each subsequent annual rebalancing, the number of bonds in each would be doubled to ten. At the end of March, it held 35 bonds, and at its next rebalance in June, that number will be increased to 40. During the quarter, it was the best performing short-term bond fund


Continued on Page 6

Please perform your own due diligence before making investment decisions. The contents of this newsletter do not constitute a recommendation to buy or sell securities.
© 2017 5i Research Inc.

on our list, gaining 0.8%. The main reason for this is the fund's corporate bond focus, which has resulted in a higher yield to maturity than its more diversified peers. I like this fund for its simple, easily understood approach, its lower than average cost, and its corporate focus, all of which I believe will help it hold up when we start to see an uptick in interest rate volatility.

**Dynamic Advantage Bond Fund (DYN 258 – Front End Units)** – This is a fund that I like, but has really tested my patience in the past few quarters. The managers have an active duration management strategy that, at least as I understand it, is supposed to be managed based on their outlook for the rate market. When they see opportunity, the duration is to be lengthened a bit, and shortened when they see trouble. While some of this may have been happening, the results have been very uninspiring relative to some of their more "index-like" peers. However, when we have seen periods of volatility and higher yields, it has done exactly what it was supposed to do. While I am tempted to replace this with a better performing, or lower cost fund, I must keep reminding myself why I liked the fund in the first place, which is its defensive positioning, and conservative approach. It has lived up to both of those, unfortunately in hindsight, it appears both they, and I have been way early on our call. In the meantime, I am watching this fund closely and have recently identified another option that has a similar objective, and have initiated my due diligence review.

**Mawer Balanced Fund (MAW 104 – No Load Units)** – Mawer runs this like a fund of funds, providing exposure to several of the firm's mandates. At the end of March, it held roughly 33% in fixed income, 18% Canadian equity, 20% U.S. equity, 19% international equity, and 7% in global small caps and the remaining roughly 4% was held in cash. It was this equity tilt that and helped the fund in the first quarter, gaining 3.6%, outpacing most of the peer group. These results are being helped by the pure quality of the underlying holdings. Mawer continues to be one of the premier investment firms in the country, with a disciplined, repeatable process that looks to find well managed, wealth creating companies that are trading at attractive valuations. They have had a few months recently where they have lagged their peers, but this is more a function of the market rewarding more highly valued, high beta, lower quality names at the expense of more reasonably valued, quality focused offerings. Going forward, as the markets return to a more normalized trading pattern, I would expect this fund to continue to deliver above average risk adjusted returns for investors.

**Leith Wheeler Canadian Equity Fund (LWF 002 – No Load Units)** – Leith Wheeler is one of those firms you don't often hear too much about. Based in Vancouver, this value-focused shop quietly goes about the business of managing money. This is their flagship Canadian equity offering, managed by the firm's equity team. They tend to have a longer-term view when evaluating an investment idea, and look at it as if they were going to buy the entire company. They like simple, easy-to-understand, well-managed businesses that are trading at what they believe to be attractive prices. They will invest in companies of any size, and are benchmark agnostic, meaning they tend to look nothing like their respective benchmark. The process works well over the long-term, as they have posted numbers that have handily outpaced their peer group. Shorter term numbers tend to be less meaningful, because of their longer-term focus. A drawback to their concentrated, all-cap style is it can often result in volatility that is well above the broader market. But if you have the stomach to live with this higher volatility, and a time horizon of at least seven to ten years, I believe you'll do quite well in this fund.


Continued on Page 7

Please perform your own due diligence before making investment decisions. The contents of this newsletter do not constitute a recommendation to buy or sell securities.
© 2017 5i Research Inc.

**Beutel Goodman Small Cap Fund (BTG 799 – No Load Units)** – Like Leith Wheeler discussed above, this is another well-respected investment manager that flies under the radar. Based in Toronto, Beutel Goodman runs a concentrated portfolio of well-managed, Canadian small and mid-cap companies that are trading well below their true value. Before a stock can be considered for inclusion in the portfolio, it must be trading at least 50% below what they believe it to be worth, and offers a near-term catalyst that can push the stock prices significantly higher. A unique feature of their process is their sell discipline. When a name hits their price target, they automatically sell 1/3 of the position. They will undertake a new review of the company, and if there is an upward revision in growth rates, they will hold the position, but if there is not, they will sell the balance of their holdings. Performance, particularly over the long-term has been excellent, boasting a ten-year gain of 8.9% to the end of March, which is nearly double the gain in the S&P/TSX Completion Index.

**Trimark Global Endeavour Fund (AIM 1593 – Front End Units)** – One of the best performing global funds in the quarter was this Invesco offering. To the end of March, it gained 7.7%, while the MSCI AC World Mid-Cap Index gained 6.5%. In managing the fund, Jeff Hyrich and Erin Greenfield look to build a concentrated portfolio of mid-cap companies that are generally leaders in their respective industries. They look for companies with quality management, strong free cashflow generation, and sustainable competitive advantages, that are trading at reasonable valuation levels. They will typically hold around 40 names, and the portfolio is built on a stock by stock basis. Sector weights and country allocations are the by-product of this stock selection process. Looking at the portfolio, they hold overweight exposures in consumer cyclical, and industrials. During the first quarter, it was largely their industrial and healthcare names that pushed most the outperformance. Valuation numbers look attractive compared to the broader market and the peer group, providing a modestly better margin of safety. Despite the concentrated, midcap focused portfolio, volatility is in line with the index and peer group. Long-term performance numbers are strong, but it is very likely to experience periods of short-term performance that are dramatically different than the index or peer group. Another drawback to the fund is it is somewhat pricey, carrying an MER of 2.58%, slightly above the category average. While I likely wouldn't use this as a core equity holding, it can be a great addition to an otherwise well diversified portfolio, to enhance both return and diversification potential.

**Manulife Global Infrastructure Fund (MMF 4569 – Front End Units)** – The mid to long-term outlook for infrastructure is very strong, with many governments including both Canada and the U.S. recently announcing increased spending. That enthusiasm has not been lost on this fund, which to the end of June gained 6.4%, in line with other infrastructure funds. A key reason I like this fund over some of its peers is the fact it is managed by Brookfield Investment Management, a respected name in the space. Initially I had hoped the strong management would offset the higher cost of this fund. But, since adding it to the Recommended List, it has failed to outpace its peers. I have begun a more detailed review of the space, and will look to see if a better infrastructure option is available. Stay tuned…


Continued on page 8

Please perform your own due diligence before making investment decisions. The contents of this newsletter do not constitute a recommendation to buy or sell securities.
© 2017 5i Research Inc.

| FUND | FIRST MENTION | RESULTS (to Mar 31) | Q1 Return | COMMENTS |
|---|---|---|---|---|
| **Bond Funds** | | | | |
| PIMCO Monthly Income Fund | Jul-15 | 8.6% (1 Yr.) | 2.5% | Strong quarter. Added some EM exposure. Duration lowered to 3.33 yrs. |
| PowerShares 1-5 Yr Laddered Corp Bond | Apr-15 | 1.5% (1 Yr.) | 0.8% | Above average returns despite modestly higher duration |
| TD Canadian Core Plus Bond | Oct-13 | 2.8% (3 Yr.) | 0.9% | Lagged despite higher weighting to corporate bonds. Remains solid pick |
| Dynamic Advantage Bond | Apr-13 | 1.4% (3 Yr.) | 0.1% | Becoming very frustrated by lack of performance. Duration remains short |
| RBC Global Corporate Bond | Jan-13 | 2.8% (4 Yr.) | 1.2% | Portfolio quality remains high. Modest exposure to high yield. |
| PH&N Total Return Bond | Aug-08 | 5.2% (8 Yr.) | 1.2% | Remains top core pick. Well positioned for environment. |
| PH&N Short Term Bond & Mortgage | May-00 | 3.7% (15 Yr.) | 0.6% | Excellent team at the helm. Well positioned. Series D units most attractive |
| **Balanced Funds** | | | | |
| Sentry Conservative Balanced Income | Apr-15 | 5.9% (1 Yr.) | 1.0% | Lacklustre start thanks largely to energy names. 45% in bonds. |
| Mawer Balanced Fund | Jun-14 | 4.9% (2 Yr.) | 3.6% | Overweight to equities, with large cap, foreign bias boosted Q1 gains |
| Steadyhand Income | Oct-10 | 5.7% (6 Yr.) | 1.3% | Managers focusing on higher quality bonds. 26% invested in stocks. |
| Fidelity Canadian Balanced | Feb-08 | 5.8% (9 Yr.) | 1.5% | Higher bond weight was a headwind compared to peers. |
| **Income Funds** | | | | |
| Sentry Canadian Income Fund | Apr-16 | 6.9% (1 Yr.) | 0.5% | Energy & industrials were laggards in Q1. About a third in U.S. names |
| CI Signature High Income | Jan-12 | 6.4% (5 Yr.) | 1.5% | Cash sitting at roughly 6% and bonds are 47%. Remains defensive. |
| BMO Monthly Dividend | Oct-03 | 2.8% (10 Yr.) | 5.8% | Energy prefs had a great Q1. Recovering, but concerns remain. Caution |
| **Canadian Equity Funds** | | | | |
| Manulife Dividend Income Fund | Apr-16 | 14.1% (1 Yr.) | 3.4% | All cap with a growth tilt. Valuations looking a bit rich. Take profits |
| CI Cambridge Canadian Equity Class | Apr-14 | 8.3% (3 Yr.) | 1.3% | Manager used rally to take profits in cyclicals. Remain defensive. 11% cash |
| Fidelity Canadian Large Cap | Oct-11 | 11.8% (5 Yr.) | 0.2% | Quality, defensive positioning weighed. Good pick for long-term. |
| RBC North American Value | Jun-11 | 10.7% (5 Yr.) | 2.6% | Nearly 40% invested in US. Large cap focus. Remains strong pick. |
| Fidelity Dividend | Sep-08 | 11.2% (8 Yr.) | 0.8% | Financial dragged in Q1. Diversified portfolio. Remains good choice |
| Leith Wheeler Canadian Equity | Jun-06 | 5.0% (10 Yr.) | 1.8% | Disciplined, value focused approach. More volatile than peers. |
| Mawer Canadian Equity | Jan-05 | 8.1% (10 Yr.) | 2.1% | Management seeing opportunities in Financials. Remains a great pick. |
| **Canadian Small Cap Funds** | | | | |
| CI Cambridge Pure Canadian Equity | Apr-15 | 19.0% (1 Yr.) | -2.1% | Energy names dragged in Q1. Remain defensive with 20% cash. |
| IA Clarington Canadian Small Cap | Oct-14 | 6.9% (2 Yr.) | -0.4% | Overweight energy hurt. Focusing on quality businesses for long-term |
| Sentry Small Mid Cap Income | Jan-13 | 13.9% (4 Yr.) | 4.3% | Strong quarter with wide contribution. Remains a great pick |
| Beutel Goodman Small Cap | Oct-03 | 8.7% (10 Yr.) | 6.3% | Disciplined process. Positioned for growth. Attractive valuations. |
| **U.S. Equity Funds** | | | | |
| Mawer U.S. Equity Fund | Apr-16 | 15.3% (1 Yr.) | 4.7% | Focus on quality, wealth creating companies. Strong quarter on tech. |
| Fidelity Small Cap America | Apr-14 | 13.4% (3 Yr.) | 3.0% | High cash was headwind. Holds dry powder, patient for opportunities |
| TD US Small Cap Equity | Jan-11 | 15.3% (6 Yr.) | 2.0% | Has a strong growth bias. Valuations look rich. Take profits! |
| Beutel Goodman American Equity | Feb-09 | 17.6% (8 Yr.) | 7.8% | Top US equity pick. Strong management & process. Well positioned. |
| **International/Global/North American Funds** | | | | |
| Fidelity Northstar Fund | Apr-16 | 5.5% (1 Yr.) | 2.3% | High cash balance was headwind in Q1. Sitting on lots of dry powder. |
| IA Clarington Global Equity Fund | Jan-15 | 6.2% (2 Yr.) | 3.1% | Managers remain cautious, and are having trouble finding opportunities |
| Mackenzie Ivy Foreign Equity | Jun-13 | 8.5% (3 Yr.) | 3.7% | Manager sitting on 30% cash, a headwind in Q1. Quality focus. |
| Trimark Global Endeavour | May-11 | 14.2% (5 Yr.) | 7.7% | Strong quarter. Valuations remain a concern. They remain patient. |
| Dynamic Power Global Growth | May-11 | 13.5% (5 Yr.) | 18.1% | Win big / lose big. Concentrated. Overweight tech & consumer cyclical |
| Mawer International Equity | Oct-09 | 10.8% (7 Yr.) | 7.9% | Some quality names posted strong gains. Remains top pick |
| **Sector Funds** | | | | |
| Manulife Global Infrastructure Fund | Apr-15 | 14.0% (1 Yr.) | 6.4% | Renewed enthusiasm for infrastructure. Looking at other options in sector |
| BMO Asian Growth & Income | Apr-13 | 5.8% (3 Yr.) | 8.1% | Strong start to year in Asian markets. Balanced approach. Strong pick |


Please perform your own due diligence before making investment decisions. The contents of this newsletter do not constitute a recommendation to buy or sell securities.
© 2017 5i Research Inc.